Castle Biosciences said a multicenter, peer reviewed study validated its DecisionDx SCC test for high risk cutaneous squamous cell carcinoma, supporting more accurate risk classification. The data were published in JAAD.
published
Castle Biosciences said a multicenter, peer reviewed study validated its DecisionDx SCC test for high risk cutaneous squamous cell carcinoma, supporting more accurate risk classification. The data were published in JAAD.
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.